An improved method of transcutaneous cisterna magna puncture for cerebrospinal fluid sampling in rats

Bederson, 1986, Rat middle cerebral artery occlusion: evaluation of the model and development of a neurological examination, Stroke, 17, 472, 10.1161/01.STR.17.3.472 Berg, 2002, Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity, J Neurosci Methods, 116, 99, 10.1016/S0165-0270(02)00033-X Chaurasia, 2007, AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives, Pharm Res, 24, 1014, 10.1007/s11095-006-9206-z Consiglio, 2000, Technique for collecting cerebrospinal fluid in the cisterna magna of non-anesthetized rats, Brain Res Protoc, 5, 109, 10.1016/S1385-299X(99)00062-8 de Boer, 2005, In vivo methods to estimate drug transport to the brain across the blood–brain barrier, Med Chem Rev Online, 2, 127, 10.2174/1567203053586973 Di, 2008, Strategies to assess blood–brain barrier penetration, Expert Opin Drug Discov, 3, 677, 10.1517/17460441.3.6.677 Frankmann, 1987, Sodium appetite and cerebrospinal fluid sodium concentration during hypovolemia, Appetite, 9, 57, 10.1016/0195-6663(87)90053-5 Garberg, 2005, In vitro models for the blood–brain barrier, Toxicol In Vitro, 19, 299, 10.1016/j.tiv.2004.06.011 Golden, 1993, Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis, Pharm Res, 10, 1765, 10.1023/A:1018982300285 Harnish, 1988, Reduced cerebrospinal fluid production in the rat and rabbit by diatrizoate. Ventriculocisternal perfusion, Invest Radiol, 23, 534, 10.1097/00004424-198807000-00010 Hosoya, 2004, A new in vitro model for blood–cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat, Adv Drug Deliv Rev, 56, 1875, 10.1016/j.addr.2004.07.013 Huang, 1995, A new approach for multiple sampling of cerebrospinal fluid in rodents with minimal trauma and inflammation, J Neurosci Methods, 63, 13, 10.1016/0165-0270(95)00080-1 Lai, 1983, Sampling and analysis of cerebrospinal fluid for chronic studies in awake rats, J Appl Physiol, 54, 1754, 10.1152/jappl.1983.54.6.1754 Lange, 2002, Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain, Clin Pharmacokinet, 41, 691, 10.2165/00003088-200241100-00001 Lebedev, 2004, Spatial characteristics of cisterna magna in rats and novel technique for puncture with a stereotactic manipulator, Bull Exp Biol Med, 137, 635, 10.1023/B:BEBM.0000042732.00810.01 Lin, 2008, CSF as a surrogate for assessing CNS exposure: an industrial perspective, Curr Drug Metab, 9, 46, 10.2174/138920008783331077 Liu, 2008, A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse, J Vis Exp, 21 Maurer, 2005, Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice, Drug Metab Dispos, 33, 175, 10.1124/dmd.104.001222 Mori, 1992, Comparison of anticonvulsant effects of valproic acid entrapped in positively and negatively charged liposomes in amygdaloid-kindled rats, Brain Res, 593, 329, 10.1016/0006-8993(92)91330-H Myers, 1977, Chronic methods: intraventricular infusion, cerebrospinal fluid sampling, and push–pull perfusion, 281 Nirogi, 2009, A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system, J Neurosci Methods, 178, 116, 10.1016/j.jneumeth.2008.12.001 Shen, 2004, Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics, Adv Drug Deliv Rev, 56, 1825, 10.1016/j.addr.2004.07.011 Stapleton, 2008, Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates, Cancer Chemother Pharmacol, 61, 647, 10.1007/s00280-007-0519-3 Yu, 1992, Dose-dependent inhibition in plasma protein binding of valproic acid during continued treatment in guinea-pigs, J Pharm Pharmacol, 44, 408, 10.1111/j.2042-7158.1992.tb03634.x